# Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

> **NCT04778982** · — · TERMINATED · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 4 (actual)

## Conditions studied

- HER2-positive Metastatic Breast Cancer

## Interventions

- **DRUG:** KN026 combined with Palbociclib and Fulvestrant

## Key facts

- **NCT ID:** NCT04778982
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-25
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-03-15
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Difficulty in completing enrollment within the planned time
- **Last updated:** 2023-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04778982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04778982, "Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04778982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*